PSS38 Drug Utilisation And Healthcare Resources Use In Patients With Psoriatic Arthritis And Psoriasis  by Degli Esposti, L et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A421
infliximab, ustekinumab) was explored. From the annual eligible psoriasis popula-
tion (N= 16,322), 5% (n= 816), 11% (n= 1,795), and 18% (n= 2,938) were assumed to 
be treated with apremilast for the first, second, and third years. A local expert 
panel provided detailed resource consumption information. Total cost included 
drug acquisition based on drug doses from summaries of product characteristics 
(ex-factory price with mandatory deduction), administration (parenteral drugs), 
and monitoring costs. Unitary costs (€ , 2014) were obtained from national data-
bases. Results: Total budget for the scenario without apremilast was € 193,677,634, 
€ 192,945,426, and € 192,077,291 in the first, second, and third years. Pharmaceutical 
cost represented 95% of the total. Following apremilast introduction, total budgets 
were reduced by € 2,194,450, € 4,827,791, and € 7,900,021 in the first, second, and 
third years. Incremental drug costs/patient comparing the scenario with apremi-
last vs. without apremilast were € −134.44 (−1.13%), € −295.78 (−2.50%), and € −484.00 
(−4.11%) in the first, second, and third years. ConClusions: Apremilast treatment 
for psoriasis patients who have failed to respond to, have a contraindication to, or 
are intolerant of other systemic therapy would imply a budget impact decrease on 
overall healthcare expenditure for NHS. This analysis was limited in that the model 
did not consider cost-effectiveness issues.
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objeCtives: This analysis was designed to estimate the budget impact following 
the introduction of apremilast in the treatment of moderate to severe chronic plaque 
psoriasis for adult patients who have failed to respond to, have a contraindication 
to, or are intolerant to other systemic therapy in Italy. Methods: A budget impact 
model was adapted to the Italian setting using local epidemiological and cost data 
to assess the financial impact of the introduction of apremilast to the market for the 
Italian National Health Service (NHS). The analysis was conducted over a 3-year time 
horizon considering year 2016 as baseline. We used real data of market consumption 
(IMS 2014 data), reflecting the budget holder’s perspective and a real-world 2015 study 
concerning the healthcare resource consumption related to each treatment included 
in the analysis (apremilast, etanercept, infliximab, adalimumab, or ustekinumab). 
Market penetration of apremilast was based on manufacturer’s assumptions. Unit 
costs were taken from Italian standard sources. Frequency of screening and monitor-
ing tests was obtained from real-world data (database analysis). Results: A total of 
≈11,500 patients were considered as the model population at the first year, with an 
assumed 5%-7% annual growth rate. The introduction of apremilast over the next 3 
years, assuming a market share of 1%-5%, 10%-15%, and 15%-20%, for the first, second, 
and third year, respectively, would lead to cost savings varying from a minimum of 
€ 10,150,000 to a maximum of € 15,480,000 for the 3 years. In particular, drug savings 
account for 91% each year, whereas monitoring savings account for 3% and admin-
istration savings account for 6%. ConClusions: This analysis suggests that the use 
of apremilast for the treatment of moderate to severe psoriasis may represent a cost-
saving option for the Italian NHS over the first 3 years of utilisation.
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objeCtives: Routine clinical practice in UK patients with severe dry eye disease 
is a combination of artificial tears (AT) and ocular lubricant ointments. This study 
aims to assess the cost-effectiveness to the UK NHS of the addition of Ikervis® 
(Ciclosporin A; CsA) to routine practice for patients who have not adequately 
responded to therapy. Methods: Using a Markov framework, future health effects 
and costs were modeled. Eligible patients receive six months therapy with Ikervis® 
plus AT and ocular lubricants or AT and ocular lubricants without CsA. Upon com-
pletion, those who respond sufficiently remain on CsA treatment for the dura-
tion of the response, achieving a higher quality of life (HRQoL) and lower AT use. 
Incremental cost effectiveness ratios (ICER) were expressed in GBP (£) per QALY 
gained with costs and health effects discounted at 3.5% over a lifetime time hori-
zon. Deterministic and probabilistic sensitivity analyses were employed to assess 
the effect of uncertainty on the model. Scenario analyses including less stringent 
improvement criteria, alternative approaches to deriving response stratified utility 
values and a shorter initial trial period were performed. Results: Compared with 
AT alone, Ikervis® Resultsin a lifetime cost to the UK NHS of £934 per patient, but 
offers an additional 0.03 QALYs. The ICER is £35,805/QALY gained. At a commonly 
accepted cost-effectiveness threshold of £30,000 per QALY, Ikervis® is cost-effective 
in 32.4% of simulations. Tornado analysis showed the model is most sensitive to 
the incremental benefit on patient’s long-term HRQoL associated with respond-
ing to therapy compared with non-response. ConClusions: The modelling study 
showed that from an NHS perspective, health gains can be achieved at a low cost. 
The Ikervis® ICERs are well below the NICE’s commonly accepted cost-effectiveness 
threshold of £30,000/QALY gained, indicating that Ikervis® in the target patient 
population could represent a cost-effective intervention in the UK.
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objeCtives: This study aimed to assess therapeutic strategies in clinical practice for 
patients with psoriatic arthritis (PsA) or psoriasis and calculate related healthcare 
resources consumption. Methods: An observational retrospective cohort analy-
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objeCtives: To evaluate the cost-effectiveness of intravitreal aflibercept (IVT-AFL) 
versus intravitreal ranibizumab for the management of neovascular age-related 
macular degeneration (nAMD) in Greece. Methods: A Markov “better-eye-treated” 
model consisting of 6 health states (5 states related to vision impairment, and 
death) was adapted in the Greek healthcare setting to compare monthly (2q4) and 
bimonthly (2q8; following 3 monthly loading doses) treatment with 2 mg IVT-AFL 
with 0.5 mg ranibizumab either on a monthly basis (0.5q4) or as needed (PRN). The 
time horizon of analysis was 20 years. All patients were assumed to discontinue 
treatment at the end of the second year. Clinical inputs and utility values were 
extracted from the literature. The analysis was conducted from a payer perspec-
tive and, as such, only costs reimbursed by the payer were considered (in 2014 
euros). Costs and outcomes were discounted by 3.5% per year. The primary out-
comes were costs, quality-adjusted life years (QALYs), and the incremental cost-
effectiveness ratio per QALY gained. Probabilistic sensitivity analysis (PSA) was 
conducted. Results: IVT-AFL 2q8 was the least expensive regimen (€ 21,930) while 
ranibizumab 0.5q4 was the most expensive (€ 26,203). For all regimens, the total 
cost was driven mainly by the direct nonmedical costs, followed by drug acquisi-
tion costs. In terms of QALYs, IVT-AFL 2q4 was the most efficacious (4.057), while 
IVT-AFL 2q8 was more efficacious (4.049) than ranibizumab PRN (4.025) but less 
efficacious than ranibizumab 0.5q4 (4.052). Although IVT-AFL 2q4 was more effica-
cious than IVT-AFL 2q8, the former cost approximately € 350,000 per QALY gained 
compared with the latter. Both ranibizumab regimens were deemed inferior. PSA 
revealed that at all willingness-to-pay thresholds up to € 335,000, IVT-AFL 2q8 had 
the highest probability of being cost-effective compared with the other treatment 
strategies. ConClusions: Bi-monthly treatment with IVT-AFL may be the most 
cost-effective option for the treatment of nAMD in Greece.
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objeCtives: The objective of this analysis is to evaluate the cost-effectiveness 
of Conbercept versus Ranibizumab in treating neovascular age-related macular 
degeneration (AMD), the third leading cause of irreversible blindness worldwide, 
from China perspective. Methods: A Markov model, based on best corrected visual 
acuity (BCVA) letters, was developed to simulate the progression of neovascular 
AMD among Chinese and to predict the outcomes of Conbercept and Ranibizumab 
treatment over 1 year. The initial distribution of visual acuity was estimated 
from MARINA trial. Disease progression was characterized by a series of annual 
transitions between 5 health states referred to as 90, 75, 60, 45, 30 BCVA letters. 
A patient’s visual acuity was assumed to either increase by 15 letters, remain the 
same, decrease by 15 letters or decrease by 30 letters each year. The transition prob-
abilities of Ranibizumab were estimated based on the reported data of EXTEND II 
trial. The Transition probabilities of Conbercept were extracted from AURORA trial. 
Utility values were taken from a cross-sectional study. Cost data, including drug 
cost, administering cost and caregivers cost in different health states, were derived 
from literatures and direct physician survey. One-way sensitivity analysis was con-
ducted on selected key parameters. Results: One-year total cost was 79,189.94 and 
141,291.23 RMB for Conbercept and Ranibizumab respectively; QALY of Conbercept 
and Ranibizumab was 0.725 and 0.715 respectively. The result suggests a dominant 
ICER of -6,210,129 RMB/QALY, which indicates that Conbercept, when compared with 
Ranibizumab in Chinese AMD population, has demonstrated better efficacy and 
overall lower costs. The one-way sensitivity analysis of key parameters (unit price 
and annual injection times) didn’t change the conclusion, indicating the robust-
ness of the results. ConClusions: Compared with Ranibizumab, Conbercept is a 
cost-effective alternative for the treatment of age-related macular degeneration in 
Chinese people. Conbercept provides better efficacy with overall lower cost.
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objeCtives: This analysis was designed to estimate the budget impact following 
the introduction of apremilast in the treatment of adult patients with moderate to 
severe psoriasis who have failed to respond to, have a contraindication to, or are 
intolerant of other systemic therapy in Spain. Methods: A budget impact model 
was developed to estimate healthcare costs for adults with moderate to severe 
psoriasis over 3 years from the NHS perspective. Target population was defined 
based on epidemiological criteria; psoriasis prevalence (2.30%) and proportion of 
patients on biologic treatment (18%) were applied to national adult population sta-
tistics. Addition of apremilast to the therapeutic arsenal (adalimumab, etanercept, 
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objeCtives: Ranibizumab and dexamethasone intravitrael(DEX) implant are 
authorised treatments for treatment of DME in Turkey. The objective of this study 
is to assess the cost-effectiveness of ranibizumab vs. dexamethasone implants in 
DME treatment with public payer’s perspective. Methods: Two studies are used 
for indirect comparison to calculate the relative efficacy of ranibizumab vs. DEX 
implant over 12 months with endpoints of BVCA gains:(i)RESTORE comparing ranibi-
zumab vs. laser BVCA gains at month 12 (ii)MEAD comparing DEX implant vs sham 
injections BVCA gains at month 36. For months 12 to 36, the efficacy inputs are 
calibrated such that the trajectories of mean BCVA for the two comparators reflect 
those reported in RESTORE(extension) and MEAD respectively. Conservative transi-
tions probabilities were imposed on the ranibizumab arm, such that mean BCVA 
sustains the~8 letters gain but no further gain is assumed. These efficacy inputs 
are then validated by the MAGGIORE head to head study of ranibizumab and DEX 
implant. MAGGIORE couldn’t be used as a primary source of efficacy as the %gains 
of 10(or15 letters) were not reported. Units of resource use and withdrawal rates 
are obtained from RESTORE and MEAD. Mean number of yearly injection frequency 
for ranibizumab was 7.0, 3.9, 2.9 for year 1, year 2 and year 3 respectively;while for 
DEX implant yearly injection frequency was 2.4 for all three years. Unit costs of 
resources were obtained by using national fees per service lists and discounted by 
3.5% Results: Mean BCVA change from baseline at year 3 with ranibizumab arm 
was 7.2 and with DEX implant arm was 2.5 points. Incremental cost of gaining an 
extra year without visual impairment by treating with ranibizumab rather than DEX 
implant is 11.339TL. ConClusions: Although conservative approach was pursued 
both in terms of efficacy for ranibizumab arm, incremental cost of gaining an extra 
year without visual impairment by treating with ranibizumab was negligible.
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objeCtives: To estimate the cost-effectiveness of secukinumab ( Cosentyx®) com-
pared with ustekinumab (Stelara®) in patients with moderate to severe plaque pso-
riasis from a Swedish societal perspective. Methods: A cost-minimization analysis 
was conducted to estimate the total treatment costs (including drug acquisition, 
monitoring and indirect costs) of secukinumab versus ustekinumab over periods up to 
ten years. Indirect costs were measured by estimated work productivity loss in three 
improvement categories incl. PASI < 50, PASI 50-74, PASI> 75. Data on PASI responses 
were based on head-to-head trial (CLEAR). Primary outcomes were total treatment 
costs over a time horizon of 1-10 years, and total costs per patient achieving PASI75 
and PASI90 (achieving clear or almost skin). Sensitivity analysis was performed to test 
the robustness of the model. Results: Secukinumab had higher treatment initia-
tion costs, but lower maintenance costs than ustekinumab. From year 2 onwards, 
secukinumab was cost-saving compared to ustekinumab. Total treatment costs after 
2 years were 338’022SEK and 339’550SEK for secukinumab and ustekinumab respec-
tively, resulting in savings of 1’529SEK. Extending the time period to 10 years resulted 
in savings of 50’460SEK. Based on the CLEAR study, a significantly higher propor-
tion of patients reached PASI75 and PASI90 with secukinumab vs ustekinumab (93% 
and 83% PASI75; 79% v 58% PASI90). Considering a 2-year time horizon, the average 
total cost per patient reaching PASI75 was 363’020SEK for secukinumab compared 
to 410’647SEK for ustekinumab. Corresponding numbers for PASI90 were 427’648SEK 
and 589’375SEK. Univariate sensitivity analyses showed that base-case Resultswere 
robust. ConClusions: From a Swedish societal perspective, secukinumab was 
estimated to be cost-saving compared with ustekinumab. In addition to the lower 
total costs from year two onwards secukinumab has shown superior efficacy on PASI 
improvement and quality of life for patients, and can therefore be considered as the 
dominant treatment compared to ustekinumab.
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objeCtives: Oral Isotretinoin (OI) is the gold standard for treating severe nodular 
acne but is associated with a significant adverse events burden. In the 20-week POWER 
trial, Adapalene 0.1% / Benzoyl Peroxide 2.5% (A/BPO), a topical fixed-dose combina-
tion treatment, plus oral antibiotic doxycycline 200mg/day (D+A/BPO) demonstrated 
a favourable composite efficacy/safety profile compared to OI in severe nodular acne 
patients. The objective of the present study was to assess the one-year cost-effec-
tiveness of D+A/BPO versus OI. Methods: A Markov model was developed for the 
Swedish setting based on clinical effectiveness data from the POWER trial and the 
typical treatment pathway patients experience following treatment failure, discon-
tinuation or relapse. Patients’ acne was classified as “controlled” following at least 
2-grade improvement in the Investigator’s Global Assessment. Health state utility 
values (HSUV) for controlled and uncontrolled acne were estimated by applying the 
Swedish tariff to the EuroQOL five dimensions questionnaire responses collected 
at baseline and study end, although the difference in the two HSUVs was minimal. 
Adverse events observed in the POWER study were included, with impact on costs 
and quality of life. Results: D+A/BPO treatment was less costly than OI at 17,033 SEK 
versus 21,185 SEK per patient. Costs Resultsfavoured D+A/BPO due to the lack of costs 
associated with monitoring when receiving OI as well as lower adverse events treat-
ment costs, combined with lower frequency and cost of physician visits as patients 
treated with D+A/BPO consult a general practitioner rather than a dermatologist. The 
total number of Quality-Adjusted Life Years accrued over one year was comparable at 
0.9250 for D+A/BPO and 0.9318 for OI. Sensitivity analyses showed that D+A/BPO was 
no longer less costly when increasing the associated frequency of physician visits or 
decreasing visits with OI. ConClusions: For severe nodular acne patients, D+A/BPO 
may be considered an attractive, lower-cost, first-line alternative to OI.
sis was conducted based on administrative databases from 2 Italian local health 
units (LHUs), ≈1.6 million beneficiaries. Citizens who were diagnosed with PsA or 
psoriasis and had a biologic prescription from January 1, 2010, to December 31, 2013 
(index date) were included. Patients were classified as biologic-naïve or biologic-
established according to previous biologic treatment, and analysed 1 year back 
to assess resource consumption in the 2 groups. Results: According to findings 
from the 2 LHUs, 86% of biologic-naive patients had previous disease-modifying 
anti-rheumatic drug (DMARD) prescriptions and 47% had previous topical anti-
psoriatic prescriptions. Exposure to DMARDs and anti-psoriatic drugs was lower 
in biologic-established patients (43% and 33%, respectively). Yearly incidence of 
disease-related hospitalisations before the index date was 7% in biologic-naive 
and 13% in biologic-established patients. Biologic-naïve patients had longer aver-
age hospital lengths of stay. The average cost of illness in the 12 months before the 
first biologic prescription (biologic-naïve) was ≈760€ , with 530€ for DMARDs, 130€ 
for anti-psoriatics, and 101€ for inpatient stays. Non-PsA/psoriasis-related costs 
were 790€ , of which 57% were due to hospitalisations. Biologic-established patients’ 
yearly expenditure accounted for 10,410€ for biologic treatment, 265€ for other PsA/
psoriasis drugs (168€ DMARDs, 70€ anti-psoriatics, 26€ corticosteroids), and 410€ 
for hospitalisations. Non-disease-related expenditure was 630€ , with > 80% due to 
drug consumption. ConClusions: At the index date, consumption of DMARDs and 
other anti-psoriatics was lower in biologic-established than biologic-naïve patients 
(43% vs 86% and 33% vs 47%, respectively), but overall drug expenditure was higher 
due to biologic acquisition cost (10,410€ vs 760€ ). Disease-related hospitalisations 
were higher in biologic-established patients treated the year before the index date 
(13% vs 7% of biologic-naïve patients).
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objeCtives: Caries is the most common dental disease in industrial countries. 
Health expenditures for the treatment of caries were estimated 8.2 billion € in 2012 
in Germany. In order to prevent or at least delay progression, many prevention 
measures have been implemented at different levels. Consumption of sugar free 
gum (SFG) is one preventive measure at the individual level. The benefit of SFG in 
caries prevention is proven by numerous studies. The presented study evaluates the 
cost - effectiveness of SFG from the perspective of the patient based on copayment 
in Germany. Methods: The development of the current status in dental health care 
is projected on a time horizon of 62 years. This is compared to a scenario where the 
consumption of SFG is increased to the Finnish level of consumption. Every tooth 
can range between the stages “No caries”, “1-4 area filling”, “Partial crown”, “Crown” 
and “Bridge / Prosthesis / Implant”. Transition probabilities were calculated based 
on the epidemiological data in the DMS IV. The calculation was conducted from the 
patients´ point of view including costs for copayment. Results: An increase in SFG 
consumption to a Finnish level leads to lifetime costs for caries of 16.882,73 € per 
patient for copayment. If the SFG consumption stays at its current level, the costs 
per patient are 23.801,11 € . As a result, in Germany an increase in SFG consumption 
leads to cost savings of about 7,000 € per patient within 62 years, or annual savings 
of 111 € . ConClusions: Increasing the consumption of SFG leads to both improve-
ment of oral health and cost savings for the patient.
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objeCtives: Actinic keratosis (AK) caused by chronic exposure to ultraviolet radi-
ation, is the most common premalignant dermatological disease in adults over 
60. Topical field treatments are effective in clinical and subclinical lesions. There 
are currently three topical treatment options available in Greece: diclofenac gel 
(3%), imiquimod (5%) and a recently launched agent: Ingenol mebutate gel (IM). 
The objective of the present study was to perform a cost-effectiveness analysis of 
IM vs other topical alternatives for the treatment of AK from a Greek healthcare 
perspective. Methods: The analysis was conducted via a decision tree in order to 
calculate the clinical effects and associated costs of AK first-line treatments: IM (2-3 
days), diclofenac (3% for 8 or 12 weeks) and imiquimod (5% for 4 or 8 weeks), over a 
24-month horizon, divided in 6-month cycles, by considering a hypothetical cohort 
of immunocompetent adult patients with clinically confirmed AK on the face/scalp 
or trunk/extremities. Clinical data on the relative efficacy of the different strategies 
under consideration were obtained from a network meta-analysis, while inputs con-
cerning resource use, reflecting the clinical practice derived from an expert panel. 
All costs were calculated from a Greek third-party payer perspective. Results: 
IM 0.015% and 0.05% were both cost-effective compared to diclofenac and below a 
willingness- to-pay threshold of 30,000€ /QALY (7.857, and 4.451 € /QALY gained for IM 
0.015% compared to diclofenac 2xdaily for 8 and 12 weeks respectively). Comparing 
IM on face/scalp AK lesions for 3 days versus imiquimod (4 or 8 weeks) resulted in 
equivalent Results(22.964€ and 787€ /QALY gained) while IM use on trunk/extremi-
ties was dominant compared to imiquimod four weeks treatment. ConClusions: 
From a social insurance perspective in Greece, IM 0.015% and IM 0.05% could be 
the most cost-effective first-line topical filed treatment options in all cases for the 
treatment of Actinic Keratosis.
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